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Abstract
We reported that p62 (sequestosome 1) serves as a signaling hub in bone marrow stromal cells 
(BMSC) for the formation of signaling complexes, including NFκB, p38MAPK, and JNK, that are 
involved in the increased osteoclastogenesis and multiple myeloma (MM) cell growth induced by 
BMSC that are key contributors to myeloma bone disease (MMBD), and demonstrated that the 
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ZZ-domain of p62 (p62-ZZ) is required for BMSC enhancement of MMBD. We recently 
identified a novel p62-ZZ inhibitor, XRK3F2, that inhibits MM cell growth and BMSC growth 
enhancement of human MM cells. In the current study we evaluate the relative specificity of 
XRK3F2 for p62-ZZ, characterize XRK3F2’s capacity to inhibit growth of primary MM cells and 
human MM cell lines, and test the in vivo effects of XRK3F2 in the immunocompetent 5TGM1 
MM model. We found that XRK3F2 induces dramatic cortical bone formation that is restricted to 
MM containing bones and blocked the effects and upregulation of TNFα, an OBL differentiation 
inhibitor that is increased in the MM bone marrow microenvironment and utilizes signaling 
complexes formed on p62-ZZ, in BMSC. Interestingly, XRK3F2 had no effect on non-MM 
bearing bone. These results demonstrate that targeting p62 in MM models has profound effects on 
MMBD.
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Introduction
Multiple myeloma (MM) is a plasma cell malignancy marked by monoclonal protein 
production and lytic bone disease that is a major cause of patient morbidity. MM bone 
disease (MMBD) is marked by increased osteoclast (OCL) activity and highly suppressed or 
absent osteoblast (OB) activity. Adhesive interactions between MM cells and bone marrow 
stromal cells (BMSC) activate multiple signaling pathways in BMSC that enhance tumor 
growth and bone destruction while suppressing new bone formation and contributing to 
chemoresistance (1–5).
We reported that p62 (sequestosome 1) serves as a signaling hub in BMSC for the formation 
of signaling complexes involved in the BMSC-induced increase in osteoclastogenesis and 
MM cell growth characteristic of MMBD (6), including NFκB, p38MAPK, and JNK (Figure 
1A), and recently demonstrated that the ZZ-domain of p62 (p62-ZZ) is required for BMSC 
enhancement of MMBD (7). We recently identified a novel p62-ZZ inhibitor, XRK3F2 
(Figure 1B), using 3D homology modeling to predict the structure of the p62 protein and 
virtual screening molecular docking studies (8), and tested XRK3F2’s potential to inhibit 
MM cell growth and modulate the MM bone marrow microenvironment. We found that 
XRK3F2 inhibited murine MM cell growth, BMSC-enhancement of human MM cell 
growth, and TNFα-induced OCL formation by WT but not p62−/− OCL precursors, and that 
it’s effects were specific to p62 (9).
The current study evaluates the relative specificity of XRK3F2 for p62-ZZ, XRK3F2’s 
growth inhibition of human MM cell lines and primary human MM cells, and characterizes 
the in vivo efficacy of XRK3F2 in the immunocompetent 5TGM1 MM model. We report 
that XRK3F2 induces new bone formation in areas of high MM burden without altering non-
tumor bearing bone. To evaluate potential mechanisms by which XRK3F2 induces bone 
formation, we tested the effects of XRK3F2 on osteoblast (OB) differentiation and MM cell 
– stromal cell (pre-OB) interactions.
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Materials and Methods
Isolation of human bone marrow cells and BMSC
After obtaining informed consent, marrow aspirates were obtained from MM patients and 
healthy subjects. These studies were approved by the University of Pittsburgh and Indiana 
University IRBs. Marrow mononuclear cells were isolated and depleted of non-adherent 
cells as previously described (10, 11) and enriched for OCL precursors by CD11b 
MicroBead® selection (Miltenyi Biotec Inc., Auburn, CA). Adherent cells were processed 
as described (12) and used at passages 2 to 3. Human MM cells (>90% purity) were isolated 
by magnetic cell fractionation using anti-CD138 MicroBeads® (Miltenyi Biotec Inc.) and 
used for experiments described below. (13).
Osteoclast formation assays
CD11b+ cells were cultured with 10 ng/ml TNFα or 50 ng/ml RANKL for 48h for Western 
analyses, or for 21d for osteoclastogenesis assays, as described (10). 23C6 positive 
multinuclear cells (containing at least 3 nuclei) were scored as OCL (14).
Myeloma cell lines
MM cell lines was generously provided by Drs. Steven Rosen (MM1.S), Babatunde O. 
Oyajobi (5TGM1), Diane Jelinek (ANBL-6) Nicola Giuliani (JJN3), Suzanne Lentzsch 
(RPMI8226), and Louis Stancato (U266, H929). 5TGM1 cells were stably transfected with a 
lentiviral construct containing GFP (5TGM1-gfp) and maintained as previously described 
(12).
OB differentiation assays
Primary BMSC or MC4 cells were cultured under osteogenic conditions in the presence or 
absence of 5TGM1 cells as described (12). Relative expression of key OB differentiation 
genes was quantified using real-time PCR, as described (12). GAPDH and 18S were used as 
internal controls.
Cell proliferation assays
Primary MM cells, human MM cell lines, or murine 5TGM1-gfp cells were incubated in 96-
well plates in RPMI-1640 media with 10% FCS and varying concentrations of XRK3F2 for 
48h (human MM cell lines and primary MM cells) or 72h (murine MM cells). Viable cells 
were quantified by MTT assay (Sigma-Aldrich, St. Louis, MO), per the manufacturer. The 
IC50 was calculated from triplicate independent experiments using the Hill equation and the 
ADAPT 5 program (15).
Western blot analyses
BMSC or OCL precursor cell lysates were loaded onto 7.5% sodium dodecyl sulfate 
polyacrylamide gels (SDS-PAGE) (for V-CAM1 expression) or 10% SDS-PAGE (for cell 
signaling analyses) and electrophoresed under reducing conditions using precast gels (Bio-
Rad Laboratories, Hercules, CA), as described (16). Antibodies used for immunoblotting 
included: anti-phospho PKCζ (Thr410/403), anti-phospho IκBα (Ser32), anti-phospho p38 
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MAPK (Thr180/Tyr182) and anti-p38 MAPK, anti-PKCξ, anti-IκBα, cleaved and uncleaved 
caspases 3, 7, and 9 (all from Cell Signaling, Boston, MA, catalog numbers 9378, 2859, 
9211, 9212, 9368, 9242, respectively), anti-c-Fos, anti-NFATc1 and anti-V-CAM1 (Santa 
Cruz Biotechnology, Dallas, TX, catalog numbers sc-52, sc-7294, sc-1504, respectively), 
and anti-TNF-α (R&D Systems, Minneapolis, MN, catalog number AF-410-NA). β-actin 
was used for a control (Abcam, Cambridge, MA, catalog ab49900).
Human IL-6 and RANKL production
BMSC (2 × 105) were cultured in α-MEM-10% FCS for 48h and IL-6 and RANKL 
production in conditioned media (CM) was quantified using commercially available ELISA 
kits (IL-6, R&D Systems, and RANKL, ALPCO Immunoassays, Salem, NH), per the 
manufacturers’ instructions.
Mice
Specific-pathogen-free, male C57BL/KaLwRij mice (6–12 weeks of age) were obtained 
from Dr. Jolene Windle at Virginia Commonwealth University. Mice were maintained and 
handled in accordance with the Guide for the Care and Use of Laboratory Animals (17) on a 
protocol approved by the University of Pittsburgh IACUC. For selected experiments, 
primary murine BMSCs were isolated from these mice and cocultured with MM cell lines, 
as described (12). BMSC from p62KO−/− mice and p62+/− littermates were isolated and 
maintained as previously described (6).
In vivo efficacy of XRK3F2
1 × 105 5TGM1-gfp cells in logarithmic phase growth were inoculated into one tibia (IT) of 
C57BL/KaLwRij mice under Nembutal anesthesia. Buprenorphine was administered as an 
analgesic 2h before and for 48h after tumor cell implantation. Supplemental Figure 1 
provides a detailed schema for the in vivo studies. Briefly, animals were stratified by IgG2b 
levels two weeks after tumor implantation and treated with either XRK3F2 (27 mg/kg/day or 
40 mg/kg/day) or vehicle (0.01ml/g in 15% hydroxyl propyl β cyclodextrin in saline/day) 
intraperitoneally (IP) for 5 consecutive days/ week for 2 weeks. Mice were then followed for 
delayed effects for up to 2 weeks following treatment, or until tumors reached 2g. 12 
animals were treated per group, based on our prior experience with tumor take in this model 
(12). Doses and dosing schedules were chosen based on preliminary multidose 
pharmacokinetic studies (data not shown).. Following euthanasia, blood was collected by 
cardiac puncture, bilateral tibias and femurs removed and fixed in 10% phosphate buffered 
formalin for 48 hours and then transferred to 70% ethanol.
IgG2b concentrations
Plasma IgG2b concentrations were determined using commercially available ELISA kits, 
according to manufacturer instructions (Bethyl Laboratories, Inc., Montgomery, TX).
Radiography and micro-computed tomography (µCT)
Radiographs of formalin fixed tibiae were obtained using an XPERT 80 Digital Cabinet X-
ray System with energy range: 10-90 kV and tube current up to 1.0 mA (Kubtec Digital X-
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ray, Milford, CT, USA), and analyzed by a blinded observer. New woven bone formation 
was quantified using a microCT system (viva CT 40, Scanco Medical, Brüttisellen, 
Switzerland). Details of µCT analysis are in the supplementary methods.
Histology and histomorphometry
Hind limbs were fixed as described above and decalcified in 10% EDTA for two weeks. 
Tissues were processed as previously described (18) and sections were stained with 
hematoxylin and eosin, and tartrate resistant alkaline phosphatase (TRAP). Tumor 
localization was confirmed with anti-GFP staining (Abcam). Sections were viewed on a 
Leica DM LB compound microscope outfitted with a Q-Imaging Micropublisher Cooled 
CCD color digital camera (W. Nuhsbaum Inc, McHenry, IL).
Statistical analyses
For cell culture and µCT studies results are expressed as mean ± standard deviation. 
Significance was evaluated using a two-tailed, unpaired Student’s t-test. Representative data 
for experiments repeated a minimum of 3 times is shown. For in vivo studies, animal IgG2b 
concentrations and body weights were evaluated by ANOVA with pairwise comparisons 
using Dunnett’s T-test, Tukey’s and Fisher’s exact test. Nonparametric analyses of median 
data were performed using Kruskall-Wallis, and pair-wise comparisons were conducted 
using the Mann-Whitney test. Significance was set at p ≤ 0.05. Statistics were performed 
using Minitab statistical software (Minitab, State College, PA).
Results
Specificity of XRK3F2 for the ZZ domain of p62
p62 is composed of five domains that are critical for protein-protein interactions required for 
the formation of signaling complexes that play important roles in BMSC-support of MM cell 
growth and OCL formation (Figure 1A). We recently demonstrated that p62-ZZ is required 
for BMSC-enhancement of MMBD (9). Because BMSC-MM interactions increase TNFα in 
the MM microenvironment, and NFκB signaling is activated in BMSC as a result of MM 
cell – BMSC binding (19), we assessed the relative specificity of XRK3F2 for p62-ZZ 
domain of p62 by testing if XRK3F2 preferentially blocked TNFα rather than IL-1β-induced 
NFκB signaling, because TNFα utilizes the ZZ domain while IL-1β utilizes the TRAF6 
domain of p62 to facilitate NFκB signaling. XRK3F2 blocked TNFα but not IL-1β 
stimulated NFκB phosphorylation in MM patient BMSC (Figure 2A) and inhibited IκBα 
degradation by interfering with p-IκBα activation in MM cells treated with TNFα (Figure 
2B). XRK3F2 also significantly inhibited TNFα-enhanced VCAM-1, IL-6, and RANKL 
expression by BMSCs from MM patients compared to vehicle (Figures 2C–E).
XRK3F2 inhibits TNFα-induced osteoclast formation
To further assess the relative specificity of XRK3F2 for the ZZ domain, we next tested the 
effects of XRK3F2 on TNFα and RANKL-induced human OCL formation. We previously 
found that XRK3F2 inhibited TNFα-induced murine OCL formation by p62+/− but not 
p62−/− OCL precursors (8). XRK3F2 dose-dependently inhibited OCL formation by CFU-
GM derived from CD11b+ cells treated with TNFα at very low concentrations of XRK3F2 
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(0.1 µM) (Figure 3A). OCL formation induced by RANKL was only partially inhibited and 
required higher concentrations of XRK3F2 (1.0 to 10 µM). This was expected as RANKL 
signaling utilizes the TRAF6, p38MAPK, and ZZ domains of p62 to induce OCL formation 
(6, 20). Further, although high dose XRK3F2 (10µM) blocked OCL formation, it did not 
trigger caspase activation or other apoptosis-inducing factors in OCL precursors (data not 
shown). These results suggest that XRK3F2 predominantly inhibits OCL precursor 
differentiation.
We next assessed the effect of XRK3F2 on TNFα and RANKL-induced expression of OCL 
differentiation and activation factors in OCL precursors. Consistent with our data in BMSC 
and primary MM cells, XRK3F2 strongly inhibited TNFα, but only modestly blocked 
RANKL-induced c-Fos and NFATc1 expression (Figure 3B). To determine the mechanisms 
responsible for XRK3F2’s inhibition of TNFα-induced OCL formation, we then examined 
the effects of XRK3F2 on downstream signaling pathways induced by TNFα in OCL 
precursors. XRK3F2 inhibited PKCζ and IκBα but not p38 MAPK activation in OCL 
precursors (Figure 3C), which utilizes the p38 domain of p62.
XRK3F2 directly inhibits the growth of MM cell lines and primary multiple myeloma cells 
but does not affect BMSC viability
As we previously reported that XRK3F2 inhibits growth of MM1.S human MM cells (8), we 
next evaluated the effects of XRK3F2 on 5TGM1 murine MM cell growth, the MM cell line 
used in our in vivo model of MMBD (12), 6 human MM cell lines, and primary MM cells. 
XRK3F2 significantly inhibited the growth of all 6 human MM cell lines, and primary 
human MM cells (Figure 4A, B). (Patient characteristics are summarized in the Table). The 
IC50 of XRK3F2 for 5TGM1 cells was 4.35µM (Figure 4C), and 4.6 µM for the human 
MM1.S cell line. In addition, 5TGM1 cells accumulated XRK3F2, with peak concentrations 
in the cell pellet of 370 µM after 30 min. Cell concentrations remained above 300 µM for 24 
hours (Supplemental Figure 2).
We previously demonstrated that XRK3F2 inhibits murine MM cell growth and human 
BMSC-support of human MM cell growth (7). Therefore, we evaluated if XRK3F2 altered 
the viability and/or function of primary BMSCs from MM patients and healthy donors and 
the mechanism of it’s effects on MM cells. XRK3F2 did not alter BMSC viability (data not 
shown). XRK3F2 induced apoptosis in MM cells, as demonstrated by cleavage of caspases 
9, 7 and 3 after 16 hours (Figure 4D).
XRK3F2 induces new cortical bone formation in MMBD in vivo
Based on these encouraging results we examined the effects of XRK3F2 in an 
immunocompetent model of myeloma, as described in the Methods section and 
Supplemental Figure 1.
The t1/2 of XRK3F2 in these mice was 10.3 hours (data not shown). Consistent with prior 
studies, 77% of evaluable animals inoculated with 5TGM1 cells (27 of 35) had MM 
engraftment, as defined by end of study elevation of plasma IgG2b levels (12)., (12)Body 
weights and hematocrits did not differ among the treatment and control groups, or in animals 
receiving high and low XRK3F2 doses (data not shown). Plasma IgG2b concentrations at the 
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end of dosing were higher in all groups as compared to at stratification, indicating that MM 
burden increased regardless of if animals received XRK3F2 or vehicle.
µCT and x-ray were used to evaluate bone disease in all animals at the end of the study. Six 
of 17 XRK3F2-treated and 1 vehicle-treated animal demonstrated a marked periosteal 
reaction on x-ray, suggesting new bone formation along the tibia (Figure 5A). However, µCT 
analysis of all animals demonstrated increased cortical bone in all XRK3F2 treated animals, 
as determined by the ratio of new cortical bone volume to total bone volume (N-BV/T-BV), 
independent of XRK3F2 dose (Figure 5C). µCT findings were confirmed by histology 
(Figure 6). Trabecular bone volumes did not differ between vehicle and XRK3F2 treated 
animals. Interestingly, no new bone formation was detected in the non-MM-bearing leg of 
XRK3F2-treated animals, (Figure 5E), indicating a lack of effect on bone not involved by 
MM. XRK3F2 treated animals with tumor burdens at the end of study (based on IgG2b 
levels) displayed greater cortical bone formation than XRK3F2 treated animals with low 
tumor burden (Figure 5D). Further analyses demonstrated no reduction in the volume of the 
marrow cavity in animals with new cortical bone formation, suggesting that increased 
endocortical bone formation did not occur within the marrow space (data not shown).
Histologic analysis of tibiae confirmed the presence of new, woven bone, (bone that was laid 
down rapidly, Figure 6F), in XRK3F2-treated animals but not in vehicle treated animals 
(Figure 6A). The majority of the periosteal surface of the tibiae of these samples had new 
bone formation that was localized to one side (Figure 6B). Anti-GFP immunohistochemistry 
confirmed that MM cells closely apposed areas of new bone formation (Figure 6C). TRAP 
staining demonstrated osteoclasts in the new bone, indicating that bone remodeling occurred 
in the new bone (Figure 6E). No new trabecular bone was noted within the marrow cavity. 
Finally, in a pilot study, XRK3F2 did not induce new bone formation in mice that had not 
been injected with MM cells (data not shown).
XRK3F2 alters MM cell – BMSC cell interactions by reducing MM cell-derived TNFα in the 
myeloma microenvironment
To examine the mechanism responsible for the new bone formation observed in vivo, we 
evaluated if XRK3F2 alters production of known MM cell derived OB inhibitors, directly 
induces OB differentiation, or alters MM cell-induced suppression of OB differentiation.
5TGM1 cells were analyzed for their expression of IL-7 and TNFα, known suppressors of 
OB differentiation that are upregulated in the presence of BMSC. (In 5TGM1 cells DKK1 
expression is not upregulated by BMSC, as previously reported (12)). XRK3F2 did not 
induce TNFα or IL-7 in 5TGM1 cells cultured with XRK3F2, or induce OB differentiation 
of primary murine BMSCs or MC4 cells, a mouse calvarial pre-OB cell line, in the absence 
of MM cells, as assessed by expression of OB differentiation markers Ocn, ALP, and Runx2 
(data not shown). These results suggest that XRK3F2 affects MM cell-BMSC interactions, 
rather than either cell type individually.
MM cell-BMSC interactions activate BMSC signaling pathways that inhibit OB 
differentiation (6). Therefore, we evaluated if XRK3F2 alters MM cell-induced inhibition of 
OB differentiation. MC4 cells were cocultured with 5TGM1 cells under osteogenic 
Teramachi et al. Page 7
Leukemia. Author manuscript; available in PMC 2016 May 18.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
conditions with or without XRK3F2. Coculture of MC4 cells with 5TGM1 cells suppressed 
Runx2 mRNA expression in MC4 cells. However, Runx2 expression in MC4 cells 
cocultured with MM cells and XRK3F2 was significantly higher than Runx2 expression in 
MC4 cells cocultured with MM cells in the absence of XRK3F2 (Figure 7A), demonstrating 
that XRK3F2 blocked MM cell induced suppression of OB differentiation.
Because XRK3F2 blocks TNFα-mediated OCL formation, and TNFα is a major suppressor 
of OB differentiation that is upregulated in the marrow microenvironment by MM cell–
stromal cell interactions, we hypothesized that XRK3F2 reduces OB suppression (allowing 
differentiation) in the MM bone marrow microenvironment by altering production of TNFα. 
5TGM1 cells were cocultured with mBMSC in the presence or absence of XRK3F2. At the 
end of the culture period, TNFα expression in 5TGM1 cells and mBMSC was evaluated by 
qPCR. TNFα mRNA expression was significantly upregulated in both 5TGM1 cells and 
BMSCs following coculture. Interestingly, XRK3F2 prevented coculture-induced 
upregulation of TNFα mRNA in 5TGM1 cells (Figure 7B) and mBMSC. in BMSCs. To 
confirm these findings at the protein level, and to determine if this reduction in TNFα 
upregulation was mediated by inhibition of p62 signaling, we repeated the experiment using 
BMSC from p62KO (p62−/−) and p62+/− mice. TNFα expression was upregulated in p62+/− 
BMSC cocultured with 5TGM1 cells, and XRK3F2 reduced this upregulation by 40% after 
12 hours of treatment. The upregulation of TNFα observed following coculture of p62−/− 
BMSC and 5TGM1 was only modestly reduced (20%) by XRK3F2 (Figure 7C). These 
findings are consistent with our prior data that XRK3F2 targets p62, and suggest that 
XRK3F2’s effect on stromal cell-induced TNFα upregulation in MM cells and BMSCs 
requires p62.
Discussion
MMBD is characterized by an uncoupling of bone remodeling and persistent OBL 
suppression (5) that results in pathologic fractures and severe bone pain. Current treatment 
strategies focus on OCL inhibition, and to date no bone anabolic agent in MM has been 
identified that results in significant new bone formation in MM lesions. We recently reported 
that p62 plays a critical role in BMSC support of MM cell growth and OCL formation (9) 
and identified the p62-ZZ domain, a RIP binding domain involved in atypical PKC and 
NFkB signaling induced by TNFα (21), as a potential therapeutic target for MM and 
MMBD.
In this study we demonstrate that XRK3F2, a novel small molecule antagonist of the p62-ZZ 
domain (9), inhibited the growth of primary CD138+ MM cells and human MM cell lines by 
inducing apoptosis, did not inhibit BMSC growth or induce BMSC apoptosis in an 
immunocompetent model of MMBD. Importantly, XRK3F2 induced dramatic, local new 
bone formation in bones bearing MM in vivo but did not induce new bone formation in 
bones from the same animals that were not directly inoculated with MM cells. The results 
demonstrate that XRK3F2 alters the effect of MM on bone.
Possible mechanisms for the bone anabolic effects we observed include direct effects of 
XRK3F2 on OBL or decreased production of OBL inhibitory factors by MM cells. Direct 
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effects of XRK3F2 on OBL are unlikely, as preliminary studies of XRK3F2 on OBL 
precursors in the absence of MM cells did not change OBL differentiation (data not shown), 
and XRK3F2 did not have an anabolic effect on bones without tumor. XRK3F2 treatment of 
MM cells also did not alter production of MM cell-derived OBL inhibitory factors, including 
TNFα and IL-7. Interestingly however, coculture of 5TGM1 cells with MC4 cells under 
osteogenic conditions in the presence of low concentrations of XRK3F2 resulted in 
upregulation rather than suppression of stromal cell Runx2, a critical transcription factor 
required for OBL differentiation that is normally suppressed with MM cell coculture (Figure 
7A) (12, 22).
These data suggest that XRK3F2 induces new bone formation by blocking the effects of 
MM cell-derived inhibitors of OBL differentiation in BMSC, such as TNFα, which use 
signaling complexes formed on the ZZ-domain of p62. In support of this hypothesis, we 
found that XRK3F2 decreased primary MM patient BMSC production of VCAM-1 (Figure 
3A), which mediates adhesive interactions between BMSCs and α4β1 integrin on MM cells 
(23) and plays an important role in BMSC support of tumor growth and MMBD (1, 6, 24–
26), via it’s effects on TNFα-induced RANKL, and IL-6 (Figures 2D, 2E). Our finding that 
XRK3F2 blocked TNFα induced PKCς and IκBα phosphorylation in BMSCs when the cells 
were pre-treated with XRK3F2 (27), but only partially blocked IL-6 and RANKL 
production, suggests that both NFκB and p38MAPK signaling regulate IL-6 and RANKL 
production by TNFα in BMSCs. Additionally, we previously reported that IL-6 and RANKL 
production are dependent on both p38MAPK and NFκB signaling in MM patient BMSCs 
(6). These results suggest that XRK3F2 may block the TNFα-induced suppression of OBL 
differentiation observed in MM cell–BMSC co-cultures (28), as XRK3F2 blocks TNFα 
mediated signaling in BMSC (Fig 3B), and upregulation of TNFα in both MM cells and 
BMSC when they are co-cultured (Figure 7B, C).
Importantly, OCL were present in the newly formed bone observed in our study. This 
demonstrates that the new bone had undergone active remodeling that could become normal 
lamellar bone over time, and that OCL activity in areas of new bone formation is not 
inhibited. It is likely that the OCL activity seen in the presence of XRK3F2 is induced by 
RANKL, as RANKL induction of OCL formation is dependent on both TRAF6 (TBS 
domain of p62) and p38MAPK (p38 domain of p62) signaling (6, 20). Consistent with this, 
XRK3F2 only modestly inhibited RANKL-induced OCL formation in vitro (Figure3A), 
though low concentrations of XRK3F2 inhibited TNFα – induced OCL formation. In 
addition, XRK3-F2 blocked OCL precursor differentiation to a lesser extent in the presence 
of RANKL (Figure 3C), but did not induce precursor apoptosis (XRK3F2 did not trigger 
caspase activation or induce apoptosis in OCL precursors, data not shown). This suggests 
that p62 is critical for normal human OCL precursor differentiation but not survival, and is 
supported by the finding that p62KO mice have normal basal OCL formation (29).
In our study, new woven bone formation occurred outside of the marrow space adjacent to 
tumor, and was seen only in bones that had been directly inoculated with MM cells. Since 
OBL suppression by MM is a local event, the proximity of new bone to tumor is consistent 
with the hypothesis that XRK3F2 alters MM suppression of OBL, suggesting that XRK3F2 
allowed MM-exposed OBL to respond to anabolic stimuli released or expressed by OCL 
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during bone remodeling, and that OCL activity may be required for the anabolic effects of 
XRK3F2.
The results of XRK3F2 on MM cells in vitro also likely reflect a decrease in NFκB 
signaling. XRK3F2 directly activated caspases 3, 7, and 9 in MM cells (Figure 4D) and 
decreased NFκB signaling in MM results in the aggregation of caspase 8 and its downstream 
effector caspases (30). Thus, high concentrations of XRK3F2 induced apoptosis in MM 
cells. The immunocompetent MMBD model used to evaluate the efficacy of XRK3F2 in this 
study used animals with well-established disease (animals were implanted with MM cells 14 
days prior to treatment initiation), and end of treatment serum IgG2b levels were 
significantly higher than levels at stratification, demonstrating continued tumor growth. This 
was expected, as plasma concentrations of XRK3F2 were not maintained above the IC50 for 
murine MM cells (4.35 µM) for more than 30 minutes following the 40mg/kg dose. The 
continued tumor growth resulted in extensive bone destruction and osteolysis throughout the 
marrow space in both vehicle treated and XRK3F2 treated animals.
To our knowledge, p62 has not been previously targeted in BMSCs or myeloma cells to 
prevent tumor progression and bone destruction. We suggest that targeting p62 in MM may 
be an attractive therapeutic strategy with little or no obvious nonspecific toxicity, as our 
preliminary data suggests that targeting p62 should not block normal hematopoiesis (9), and 
p62−/− mice have no phenotype aside from adult onset diabetes (31). We anticipate that 
XRK3F2 or its derivatives, in combination with more potent anti-myeloma agents such as 
bortezomib (32, 33), should have a profound therapeutic effect on MMBD.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
A Binding domains of p62. Sequestosome 1 (p62) is an adapter protein without intrinsic 
enzymatic activity that serves as a platform for the formation of many of the signaling 
complexes that result in NFκB and p38 MAPK activation in the marrow microenvironment 
of MM patients. The ZZ domain of p62 is required for BMSC support of MM cell growth 
and acts as a signaling hub for the formation of BMSC signaling complexes activated by 
MM cells and TNFα. SH2 = Src homology 2, aPKCs = atypical protein kinase C, PB1 = 
Phox and Bem1p, RIP1 = receptor-interacting protein-1, TRAF6 = TNF receptor-associated 
factor 6, TBS = TRAF6 binding site, UBA = ubiquitin-associated domain. 1B: Structure of 
XRK3F2.
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Figure 2. XRK3F2 blocks TNFα-induced signaling processes in MM patient BMSC and MM 
cells
A. XRK3F2 blocks TNFα but not IL-1β stimulated NFkB phosphorylation on MM 
patient BMSC. MM patient BMSC were pre-treated with 10mg/ml of XRK3F2 or vehicle 
(0.1% DMSO) for 3 hours. Cells were then stimulated with 10ng/ml of TNFα or IL-1β for 
the indicated times. Phospho-NFκB (p-NFκB) and NFκB were assayed by Western blot 
using anti-phospho-NFκB and anti-NFκB antibodies. The ratio of p-NFκB to total NFκB at 
the 5 and 30-minute time points for each treatment condition is shown. B. XRK3F2 
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inhibited p-IκBα activation by TNFα in MM patient BMSCs. BMSCs were pre-treated 
with XRK3F2. For assay of degradation of IκBα, cells were stimulated with 10ng/ml of 
TNFα for the indicated times and the cell lysates were collected. Total IκBα were assayed 
by Western blot using an IκBα antibody. C. VCAM-1 expression on representative 
normal and MM patient BMSCs. VCAM-1 expression was assayed by Western blotting. 
BMSCs were cultured with and without TNFα and XRK3F2 for 48 hours. Cell lysates were 
then collected and VCAM-1 expression measured using an anti-VCAM-1 antibody. D. IL-6 
production by MM patient BMSCs. BMSCs were cultured with and without TNFα and 
XRK3F2 for 48 hours. Cell culture media were collected and IL-6 production measured 
using an IL-6 ELISA kit. Data are shown as the mean ± SD (n=3). *p<0.01 compared to 
non-treatment control culture. E. RANKL production by MM patient BMSCs. BMSCs 
were cultured with and without TNFα and XRK3F2 for 48 hours. Cell culture media were 
collected and RANKL production measured using a RANKL ELISA kit. Data are shown as 
the mean ± SD (n=3). * p<0.01 compared to vehicle treatment control culture.
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Figure 3. Effects of XRK3F2 on human OCL formation
A. XRK3F2 in combination with TNFα or RANKL significantly reduced human OCL 
formation. Human CD11b+ mononuclear cells (OCL precursors) derived from human bone 
marrow samples were cultured in α-MEM containing 20% horse serum with TNFα or 
RANKL and various doses of XRK3F2. Multi-nucleated osteoclasts were stained for 23C6, 
which recognizes CD51/61. Data are shown as mean ± SD (n=5). * p<0.01 compared to 
non-treatment cultures. B. XRK3F2 blocked c-Fos and NFATc1 activation. CD11b+ cells 
were pre-treated with XRK3F2 and OCL precursors were stimulated with TNFα or RANKL 
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in the absence or presence XRK3F2 for 48 hours. The cell lysates were collected and 
assayed for expression of c-Fos and NFATc1 using anti-c-Fos and anti-NFATc1 antibodies. 
C. XRK3F2 inhibited p-PKCζ and p-IκBα activation in OCL precursors. CD11b+ cells 
were pre-treated with XRK3F2 and stimulated with 10ng/ml of TNFα for the times 
indicated. Phospho-PKCς, IκBα and p38 MAPK were assayed using anti-phospho PKCς, 
anti-phospho IκBα and anti-phospho p38 MAPK antibodies.
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Figure 4. XRK3F2 blocks MM cell growth
A. Effect of XRK3F2 on human MM cell lines and the murine 5TGM1 cell line. Each 
cell line was treated with 10µM XRK3F2 and analyzed by MTT assay. Data are shown as 
the mean ± SD (n=5). *p<0.01 compared to cell cultures treated with vehicle. B. XRK3F2 
blocks primary MM cell growth. CD138+ cells from MM patients were treated with 10µM 
of XRK3F2 for 48 hours and analyzed for cell viability by MTT assay. Data are shown as 
the mean ± SD (n=5). *p<0.01 compared to vehicle treated cultures. C. The IC50 for 
PY1-32 against 5TGM1-gfp murine multiple myeloma cells in a 72 hour MTT assay 
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was 4.35 µM. D. XRK3F2 induced cleavage of caspase 9, 7 and 3 in MM1.S cells. 
MM1.S cells were cultured with 10µM XRK3F2 for the indicated time and cell lysates were 
collected. Cleaved and uncleaved caspases 9, 7 and 3 were detected by Western blotting 
using anti-cleaved and uncleaved caspase 9, 7 and 3 specific antibodies.
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Figure 5. XRK3F2 treatment results in new bone formation in an in vivo model of MM bone 
disease
A. Representative radiographic images of fixed tibiae from animals inoculated with 
5TGM1 MM cells (left, center) and XRK3F2, and animals that received IT 5TGM1 
injections in the absence of XRK3F2. The tibia shown with 5TGM1 inoculation and 
XRK3F2 exposure (left) has an aggressive periosteal reaction in the form of delicate rays of 
periosteal bone that extend away from the bone perpendicularly – creating a “hair on end” 
appearance (arrow). In addition, a permeative pattern of bone destruction is noted in the 
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fibula (arrowheads). This pattern of bone destruction is associated with rapid growth of the 
inciting agent, such as in cases of bone metastases and myeloma. In contrast, the center x-
ray image (tibia from the contralateral (non-5TGM1 injected) leg of an animal with MM and 
treated with XRK3F2 has no evidence of a periosteal reaction, though osteopenia is evident. 
Finally, no periosteal reaction is seen on x-ray of a tibia treated with IT 5TGM1 cells but no 
XRK3F2. Lytic lesions are visible. B. µCT images of new bone formation. Fixed tibiae 
were scanned using a microCT system (vivaCT 40, Scanco Medical). Composite µCT 
images of the volume of interest for each tibia are shown, and correlate with the bones 
whose x-ray images are above. New bone formation can clearly be seen along the tibial 
diaphysis of the tibia that had direct MM cell inoculation and XRK3F2 exposure. No new 
bone formation is seen in either the contralateral leg of an animal that did have XRK3F2 
exposure (center) or the MM-injected control that did not have XRK3F2 exposure. C. New 
bone volume is increased in all XRK3F2 treated mice. To compare new bone formation 
between vehicle and XRK3F2 treated animals, a global threshold was applied to delineate 
newly formed bone (330) from total bone (180) from surrounding soft tissue and water. The 
ratio of new (N) bone volume (BV) as compared to total BV was increased in all XRK3F2-
F2 treated mice regardless of IgG2b level (p=0.015). *p < 0.05 compared to vehicle treated 
animals. D. XRK3F2 treated mice with high tumor burden had more new bone 
formation. XRK3F2 treated mice with high monoclonal IgG2b levels (a marker of tumor 
burden) had significantly more new bone formation than animals with low IgG2b levels 
(p=0.018). *p < 0.05 compared to low IgG2b animals. E: Effects of XRK3F2 on 
uninvolved bone. To evaluate if the effect of XRK3F2 on new bone formation is systemic or 
occurs only in the presence of tumor, we compared N-BV/T-BV in the non-tumor bearing 
(left) tibiae of animals treated with vehicle or XRK3F2. New bone volume did not differ 
significantly between the groups. Data are shown as mean ± SD.
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Figure 6. Representative histologic sections from XRK3F2 treated animals with new bone 
formation (B-F) and a vehicle treated animal without new bone formation (A)
All sections shown are from animals that received MM cell inoculation. A. Sections from 
5TGM1-inoculated mice that did not receive XRK3F2 demonstrate a significant plasma cell 
infiltrate in the marrow space, as expected, and normal cortical morphology with no 
evidence of new bone formation (x50, scale bar = 500µ). B. Sections from mice treated with 
XRK3F2 stained with H&E show abundant new bone formation along the periosteal surface 
of the tibia (bracket) inoculated with 5TGM1 cells (×50, scale bar = 100µ). C. anti-GFP 
immunohistochemistry confirmed that plasma cell (5TGM1-tk-gfp) infiltration (long arrow) 
in the marrow space was in close proximity to areas of new bone formation (short arrow) 
(×16, scale bar indicates 500µ). D. Higher magnification demonstrates new bone (short 
arrows) and active osteoblasts (long arrows) (×200, scale bar = 100µ). E. TRAP stained 
section from a representative section with new bone formation shows the presence of red-
staining osteoclasts (arrows) along the new bone surface (×100, scale bar = 100µ). F. 
Polarizing microscopy demonstrates a disorganized (woven) arrangement of the newly laid 
bone, indicating that this bone was laid rapidly. (×100, scale bar = 100 microns. Collagen 
fibrils are green.)
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Figure 7. XRK3F2 blocks Runx2 downregulation and TNFα induction in cocultures of MM cells 
and BMSC expressing p62
A. XRK3F2 blocks suppression of OB differentiation in MM cell – stromal cell 
coculture. MC4 (pre-osteoblast) cells were directly cocultured with 5TGM1 cells under 
osteogenic conditions in the presence and absence of XRK3F2 for 72 hours. 5TGM1 cells 
were then removed by washing and MC4 cell lysates prepared. MC4 Runx2 mRNA 
production was analyzed by qPCR using the comparative 2−ΔΔCt method. Data is normalized 
to GAPDH and presented as mean ± SD for a typical experiment. Runx2 expression was not 
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suppressed in XRK3F2 treated MC4 cells cocultured with 5TGM1 cells. **p<0.01, N.S. no 
significant difference compared to MC4 control. B. XRK3F2 reduces upregulation of 
TNFα in MM cells cocultured with BMSC. 5TGM1 cells were cultured alone or in the 
presence of primary mBMSC cells and XRK3F2 for 48hours. At the end of the culture 
period, 5TGM1 cells were washed from the mBMSC and 5TGM1 cell lysates prepared. 
TNFα production was analyzed by qPCR and normalized to 18S. XRK3F2 significantly 
decreased mBMSC-induced upregulation of TNFα in 5TGM1 cells. C. XRK3F2 reduced 
the increase in stromal cell expression of TNFα induced by coculture with MM cells. 
We used BMSC from p62KO (p62−/−) and p62 heterozygote (p62+/−) littermates to evaluate 
if XRK3F2 alters the increased stromal cell production of TNFα following coculture with 
MM cells, and if the effect of XRK3F2 is mediated by p62. p62+/− and p62−/− BMSC were 
incubated with and without 5TGM1 cells in the presence and absence of XRK3F2 for 12 
hours. Following coculture, 5TGM1 cells were washed from the BMSC, and TNFα 
expression was assessed by Western blot. TNFα was undetectable in BMSC cultured alone, 
and upregulated to a greater extent in p62+/− than p62−/− BMSC following coculture with 
5TGM1 MM cells. TNFα expression was also undetectable in XRK3F2 treated BMSC 
cultured in the absence of MM cells. Coculture of p62+/− BMSCs in the presence of 
XRK3F2 reduced the increase in TNFα expression in BMSC while XRK3F2 did not greatly 
alter the upregulation of TNFα in p62−/− BMSC cocultured with MM cells.
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Table
Patient Characteristics
ID Age Gender Stage
1 76 Female IIA Relapsed Disease
2 77 Female III Relapsed Disease
3 65 Male III Relapsed Disease
4 69 Male IIIA Relapsed Disease
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